Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches

Area of Science:

• Ophthalmology
• Pediatric Rheumatology
• Immunology

Background:

• Chronic anterior uveitis is a significant complication in pediatric patients with early-onset juvenile idiopathic arthritis (JIA).
• Early diagnosis through regular slit-lamp examinations is critical to prevent long-term ocular damage.
• Antinuclear antibody positivity and specific JIA subtypes increase the risk of developing uveitis.

Purpose of the Study:

• To outline the diagnostic and management strategies for chronic anterior uveitis in pediatric JIA patients.
• To emphasize the importance of timely and appropriate immunomodulatory treatment to control ocular inflammation.
• To highlight the collaborative role of ophthalmologists and pediatricians in managing this condition.

Main Methods:

• Regular slit-lamp examinations (every 3 months for at least 5 years) for early detection of uveitis in at-risk JIA patients.
• Initiation of local steroid therapy as first-line treatment for uveitis.
• Introduction of systemic immunomodulatory therapy, including methotrexate (MTX) and biologics (e.g., anti-TNF-alpha), for refractory cases or prolonged steroid use.

Main Results:

• Systemic immunomodulatory therapy is often required when topical steroids are insufficient or prolonged.
• Methotrexate (MTX) is a common choice, but other biologics may be necessary for optimal control.
• Treatment intensification may be needed for surgical planning, and maintenance therapy should continue for at least 1-2 years post-remission.

Conclusions:

• A multidisciplinary approach involving ophthalmologists and pediatricians is essential for managing JIA-associated uveitis.
• Continuous and adequate immunomodulatory treatment is vital to prevent vision-threatening complications.
• Treatment duration should be carefully considered, extending well into remission to ensure sustained ocular health.